Kyowa Kirin Co., Ltd. (TYO:4151)
2,511.00
-22.00 (-0.87%)
Nov 10, 2026, 3:30 PM JST
Kyowa Kirin Revenue
Kyowa Kirin had revenue of 121.32B JPY in the quarter ending September 30, 2026, with 2.12% growth. This brings the company's total for the last twelve months to 532.32B, up 10.39% year-over-year. In the year 2025, Kyowa Kirin had annual revenue of 496.83B with 0.26% growth. That makes Kyowa Kirin the 3,544th largest company in the world by revenue and 346th in Japan.
Revenue (ttm)
532.32B
Revenue Growth
+10.39%
P/S Ratio
2.47
Revenue / Employee
103.14M
Employees
5,161
Market Cap
1.31T
Revenue by Geography
- United States 238.91B 48.1%
- Japan 128.84B 25.9%
- Europe 84.82B 17.1%
- Asia 36.29B 7.3%
- Americas (Except United States) 6.59B 1.3%
- Others 1.38B 0.3%
Fiscal year ended Dec 31, 2025 See the full Kyowa Kirin breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 496.83B | 1.27B | 0.26% |
| Dec 31, 2024 | 495.56B | 53.33B | 12.06% |
| Dec 31, 2023 | 442.23B | 43.86B | 11.01% |
| Dec 31, 2022 | 398.37B | 46.13B | 13.09% |
| Dec 31, 2021 | 352.25B | 33.89B | 10.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tsuruha Holdings | 2.17T |
| MatsukiyoCocokara & Co. | 1.13T |
| COSMOS Pharmaceutical | 1.11T |
| Sugi Holdings | 1.05T |
| Sundrug | 850.15B |
| Ain Holdings | 691.99B |
| Kusuri No Aoki Holdings | 586.17B |
| Create SD Holdings | 505.08B |
Kyowa Kirin News
- 8 days ago - Kyowa Kirin Quarterly report: Q3 2026 - Filings
- 8 days ago - Kyowa Kirin Slides: Q3 2026 - Filings
- 8 days ago - Kyowa Kirin Slides: Corporate presentation - Filings
- 26 days ago - Kyowa Kirin Reports Three-Year Real-World Data On Burosumab In Adults With XLH - Nasdaq
- 5 weeks ago - Knight Therapeutics, Kyowa Kirin enter distribution agreement for POTELIGEO - TheFly
- 5 weeks ago - Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America - Business Wire
- 5 weeks ago - Knight Therapeutics signs exclusive distribution agreement with Kyowa Kirin - TheFly
- 2 months ago - Kyowa Kirin Slides: Corporate presentation - Filings